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Abstract
This study was conducted to evaluate the effects of synbiotic supplementation on metabolic profiles in diabetic patients under-
going hemodialysis (HD). This randomized, double-blinded, placebo-controlled clinical trial was performed in 60 diabetic HD
patients. Participants were randomly assigned into two groups to receive either synbiotic capsule, containing Lactobacillus
acidophilus, Lactobacillus casei, and Bifidobacterium bifidum (2 × 109 CFU/g each), plus 0.8 g/day of inulin (n = 30) or placebo
(n = 30) for 12 weeks. Synbiotic supplementation significantly decreased fasting plasma glucose (β − 13.56 mg/dL; 95% CI, −
23.82, − 3.30; P = 0.01), insulin levels (β − 5.49 μIU/mL; 95% CI, − 6.92, − 4.05; P < 0.001), and insulin resistance (β − 2.25;
95% CI, − 3.02, − 1.48; P < 0.001), while increased the quantitative insulin sensitivity check index (β 0.02; 95% CI, 0.01, 0.02;
P < 0.001) compared with the placebo. Additionally, synbiotic intake resulted in a significant reduction in high-sensitivity C-
reactive protein (β − 2930.48 ng/mL; 95% CI, − 3741.15, − 2119.80; P < 0.001) and malondialdehyde levels (β − 0.60 μmol/L;
95% CI, − 0.99, − 0.20; P = 0.003). Moreover, we found a significant increase in total antioxidant capacity (β 142.99 mmol/L;
95% CI, 61.72, 224.25; P = 0.001) and total glutathione levels (β 131.11 μmol/L; 95% CI, 89.35, 172.87; P < 0.001) in the
synbiotic group compared with the placebo group. Overall, synbiotic supplementation for 12 weeks had beneficial effects on
glycemic control, biomarkers of inflammation, and oxidative stress in diabetic patients under HD. This study was registered in the
Iranian website (www.irct.ir) for registration of clinical trials (http://www.irct.ir: IRCT2017090133941N17). http://www.irct.ir:
IRCT2017090133941N17.
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Introduction
Diabetes mellitus is associated with a chronic inflammatory
state and accounts as a major cause of end-stage renal disease
(ESRD) [1]. The risk of cardiovascular events is higher in
diabetic patients compared to non-diabetics with ESRD [2].
Several factors including insulin resistance, elevated reactive
oxygen species (ROS), decreased antioxidant defense, infec-
tion, and comorbid conditions such as hypertension exacer-
bate the inflammatory status in patients undergoing hemodi-
alysis (HD) [3]. Recently, it has stated that the intestinal tract
and microbiota may play an important role in the systemic
inflammation detected in patients under HD [4].
Probiotics are Blive strains of strictly selected microorgan-
isms, when administered in adequate amounts can confer a
health benefit in the host^ [5]. Prebiotics are nonviable food
component that confer a health benefit throughmodulating the
host’s microbiota [5]. Synbiotics describe as a combination of
synergistically acting probiotics and prebiotics [6]. The use of
synbiotic for a number of metabolic disorders, including met-
abolic syndrome and diabetes, has recently received much
attention. Therapeutic interventions to target the intestinal mi-
crobiota are promising areas of investigation in diabetic pa-
tients undergoing HD. In addition, diabetic HD patients are in
a particular state of health and this can be affected by the
beneficial effects of synbiotics or any medical intervention.
A study conducted in ESRD patients under HD therapy has
shown that synbiotic compounds could balance the intestinal
microbiota through increasing the number of Bifidobacterium
[7]. The beneficial effects of synbiotic supplementation have
been demonstrated on insulin metabolism in patients with type
2 diabetes mellitus (T2DM) [8], non-alcoholic fatty liver dis-
ease (NAFLD) [9], rheumatoid arthritis (RA) [10], and over-
weight and obesity [11]. In addition, we have also reported
that synbiotic consumption in diabetic patients significantly
improved glucose homeostasis parameters [12], although oth-
er researchers failed to find any glycemic improvement in
response to ingesting synbiotic supplements in diabetic pa-
tients [13, 14].
The effects of synbiotics on lipid profiles in patients with
metabolic disorders are controversial. Eslamparast et al. [15]
reported that synbiotics supplementation for 28 weeks im-
proved triglycerides and total- and HDL-cholesterol in pa-
tients with metabolic syndrome (MetS), yet did not affect
LDL-cholesterol levels. Moreover, synbiotic intake in healthy
young volunteers significantly reduced triglycerides and total-
and LDL-cholesterol, while increased HDL-cholesterol levels
[16]. Conversely, we did not observe any beneficial effect on
lipid profiles following synbiotic supplementation in patients
with RA [10]. The favorable effects of synbiotics and
probiotics on metabolic profiles may be due to the microbial
production of short-chain fatty acids (SCFA), which in turn
results in increasing glucagon-like peptide-1 (GLP-1) and
inhibits postprandial hyperglycemia [17]. Moreover,
probiotics may suppress inflammation and oxidative stress
by inhibiting lipid peroxidation, modulating the pattern of
cytokine secretion from a pro-inflammatory to an anti-
inflammatory state and preserving the activity of antioxidant
enzymes [18]. However, data investigating the impact of
synbiotic on glycemic control, lipid profiles, biomarkers of
inflammation, and oxidative stress in diabetic patients under-
going HD are scarce. Therefore, this study was aimed to de-
termine the effects of synbiotic supplementation on metabolic
profiles of diabetic patients under HD.
Methods
Trial Design and Study Participants
This study was registered in the Iranian website for clinical
trials (http://www.irct.ir: IRCT2017090133941N17). It was a
randomized, double-blinded, placebo-controlled clinical trial.
This investigation was conducted in 60 diabetic patients un-
dergoing HD, 18 to 80 years old, and had been referred to the
Akhavan Clinic in Kashan, Iran, between November 2017 and
February 2018. The investigation was performed following
the Declaration of Helsinki and informed consent was taken
from all participants. This study was approved by the ethics
committee of Kashan University of Medical Sciences
(KAUMS). Pregnant women, taking probiotic and/or
synbiotic supplements, antioxidant and/or anti-inflammatory
supplements within the last 3 months prior to the enrollment in
the study; patients who required medications adjustment dur-
ing the study; and those who had recently been diagnosed with
T1DM or T2DM were excluded from the study.
Study Design
At first, participants were matched based on sex, duration of
dialysis and diabetes, BMI, and age. Patients were requested
not to change their routine physical activity or usual diets
throughout the study and not take any anti-inflammatory and
antioxidant medications or supplements during the 12-week
intervention which might affect the results of the study.
Consumption of synbiotic supplements and placebos was
monitored through asking subjects to return the medication
containers. Furthermore, a short message was being sent to
all participants’ cell phones every day to remind them using
the supplements. A 3-day food record (one weekend day and
two weekdays) and physical activity records were completed
by all participants. The individual’s nutrient intake was then
calculated and averaged at weeks 0, 3, 6, 9, and 12 of the
intervention using Nutritionist IV software (First Databank,
San Bruno, CA), the version which is modified for Iranian
foods.
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Intervention
To have more appropriate function, the strains used in probiotic
supplements for human consumption should be derived from
the human intestinal tract, well characterized, able to survive the
rigors of the digestive tract and colonized, biologically active
against the target, and stable and amenable for commercial
production and distribution [19]. These are the basic minimal
criteria that should be considered in a high-quality probiotic
supplement. Little was known about the ideal choice and the
dosage of synbiotic used for diabetic patients undergoing HD,
so we selected the supplement and its dose based on previous
published studies in diabetic patients with coronary heart dis-
ease [20] and overweight children [21]. In these trial cases (n =
30) received a synbiotic capsule containing Lactobacillus
acidophilus, Lactobacillus casei, and Bifidobacterium bifidum
(2 × 109 CFU/day each) plus 0.8 g/day of inulin for 12 weeks.
Synbiotic supplements and placebos (corn starch) were pro-
duced by Tak Gen Zist Pharmaceutical Company, Tehran,
Iran, and approved by the Food and Drug Administration.
Assessment of Anthropometric Measures
A trained staff took anthropometric measurements at the clinic
at baseline and after 12 weeks of intervention. Body weight
was measured after an overnight fast, using a calibrated digital
scale (Seca, Hamburg, Germany).
Assessment of Outcomes
In the current study, the homeostasis model of assessment-insulin
resistance (HOMA-IR) was considered as the primary outcome.
Lipid profiles, biomarkers of inflammation, and oxidative stress
were assessed as secondary outcomes. Fasting blood samples
were collected at the beginning and 12 weeks after the interven-
tion (10 mL/sample) at Kashan reference laboratory and centri-
fuged to separate serum. Then, the samples were stored at −
80 °C until analysis. Serum insulin concentrations were mea-
sured using an ELISA kit (DiaMetra, Milano, Italy) with inter-
and intra-assay coefficient variances (CVs) of less than 5%.
HOMA-IR and the quantitative insulin sensitivity check index
(QUICKI) were determined according to the standard formulas
[22]. Enzymatic kits (Pars Azmun, Tehran, Iran) were used to
quantify fasting plasma glucose (FPG), serum triglycerides,
VLDL-, total-, LDL-, and HDL-cholesterol concentrations with
inter- and intra-assay CVs of less than 5%. Serum hs-CRP con-
centrations weremeasured using a commercial ELISA kit (LDN,
Nordhorn, Germany) with inter- and intra-assay CVs of less than
7%. Plasma nitric oxide (NO) using Griess method [23], total
antioxidant capacity (TAC) by ferric reducing antioxidant power
method, developed by Benzie and Strain [24], total glutathione
(GSH) using Beutler et al.’s method [25], and malondialdehyde
(MDA) concentrations were measured using thiobarbituric acid
reactive substances spectrophotometric test [26] with inter- and
intra-assay CVs of less than 5%.
At baseline, subjective global assessment (SGA) question-
naire was explained for the participants and completed
through face-to-face interview by the main investigator of this
study (Z.A). This process was repeated by the same person at
the end of the intervention. Then, SGA classifications were
converted into numerical equivalents: a score of < 10 points
was regarded as well nourished; 10–17 points, at risk for mal-
nutrition or mildly to moderately malnourished; and scores of
more than 17 points, severely malnourished [27].
Sample Size
We used randomized clinical trial sample size calculation for-
mula, where type one (α) and type two errors (β) were consid-
ered as 0.05 and 0.20 (power = 80%), respectively. According
to the previous published trial [28], we used 1.80 as the SD and
1.45 as the mean change (d) of HOMA-IR which was the
primary outcome. Using sample size calculation formula, 25
participants were required in each group; allowing for 5 prob-
able dropouts in each group, the final sample size was calculat-
ed as 30 participants in each intervention group.
Randomization
Participants were randomized using computer-generated ran-
dom numbers. Randomization and allocation were concealed
from both researchers and patients until the completion of
final analyses. The randomized allocation sequence, enrolling
participants, and allocating them to interventions were con-
ducted by a trained nutritionist in dialysis clinic.
Statistical Methods
The Kolmogorov-Smirnov test was conducted to deter-
mine the normality of data. To detect the differences in
anthropometric measures and dietary intakes between
treatment groups, we used independent-samples t test.
Multiple linear regression models were applied to assess
treatment effects on study outcomes, after adjusting for
confounding parameters including age and BMI. The effect
sizes were presented as the mean differences with 95%
confidence intervals. P values < 0.05 were considered sta-
tistically significant. All statistical analyses were conduct-
ed using the Statistical Package for Social Science version
18 (SPSS Inc., Chicago, IL, USA).
Results
All 60 participants (30 in each group) completed the trial (Fig.
1). The compliance rate was high, since more than 90% of
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synbiotic and placebo capsules were taken by study participants
during the course of the intervention in both groups. No side
effects were reported following the consumption of synbiotic in
diabetic patients undergoing HD throughout the study.
At the beginning of the trial, study participants in two in-
tervention groups were comparable in terms of their gender,
mean age, height, weight, BMI, and years of dialysis.
Moreover, there was a significant difference between two
groups in their weight (P = 0.02) and BMI (P = 0.02) change
(Table 1). The reported consumption of anti-diabetic or anti-
lipidemic drugs, angiotensin-converting enzyme inhibitors,
aldosterone receptor blockers, phosphate binders, residual re-
nal function at baseline and rate of CVD, cerebrovascular
disease, hypertension, kidney stone, and cancer at baseline
were not statistically different between two intervention
groups at baseline or end of the trial.
We found no significant change in dietary macronutrient in-
takes, total dietary fiber, and total sugar intake throughout the
intervention, using 3-day dietary records (Supplemental file 1).
After 12-week intervention, synbiotic supplementation sig-
nificantly decreased FPG (β − 13.56 mg/dL; 95% CI, − 23.82,
− 3.30; P = 0.01), serum insulin levels (β − 5.49 μIU/mL;
95% CI, − 6.92, − 4.05; P < 0.001), HOMA-IR (β − 2.25;
95% CI, − 3.02, − 1.48; P < 0.001), and HbA1c (β − 0.44%;
95% CI, − 0.79, − 0.09; P = 0.01) and significantly increased
QUICKI (β 0.02; 95% CI, 0.01, 0.02; P < 0.001) compared
with the placebo (Table 2). Moreover, synbiotic supplementa-
tion resulted in a significant reduction in serum hs-CRP (β −
2930.48 ng/mL; 95% CI, − 3741.15, − 2119.80; P < 0.001)
and plasma MDA levels (β − 0.60 μmol/L; 95% CI, − 0.99,
− 0.20; P = 0.003), while a significant increase in plasma TAC
(β 142.99 mmol/L; 95% CI, 61.72, 224.25; P = 0.001) and
GSH levels (β 131.11 μmol/L; 95% CI, 89.35, 172.87;
P < 0.001) was observed compared with the placebo.
Synbiotic supplementation did not affect other metabolic
parameters.
Discussion
In the current study, we investigated the effects of synbiotic
supplementation on metabolic profiles in diabetic patients un-
dergoing HD. We found that taking synbiotic for 12 weeks by
diabetic patients undergoing HD significantly improved
health parameters, including glycemic control, biomarkers of
inflammation, and oxidative stress, but did not significantly
affect lipid profiles. We have previously reported beneficial
effects of probiotic supplementation containing Lactobacillus
acidophilus, Lactobacillus casei, and Bifidobacterium
bifidum in diabetic patients under HD [29]; however, the syn-
ergistic immunomodulatory and anti-inflammatory effects of
probiotics and inulin might improve the impact of probiotics
on clinical and metabolic symptoms of these patients. Indeed,
the effect sizes of 0.47, 0.35, 0.41, 0.11, 0.48, 0.15, 0.05, and
0.14 for FPG, insulin, HOMA-IR, QUICKI, HbA1c, hs-CRP,
TAC, MDA, and SGA scores in this study were generally
higher than the effects observed in the previous study with
probiotics alone, with the effect sizes of 0.12, 0.29, 0.30,
0.29, 0.08, 0.07, 0.08, 0.11, and 0.10, respectively [29].
Effects on Glycemic Control and Lipid Profiles
The findings of this study showed that taking synbiotic sup-
plements for 12 weeks by diabetic patients under HD
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significantly increased weight and BMI. In a meta-analysis
conducted by Million et al. [30], Lactobacillus acidophilus
administration led to significant weight gain in both humans
and animals models. In an animal study conducted by Heo
et al. [31], gut microbiota, modulated by probiotics and
Garcinia cambogia extract, was associated with weight gain.
The significant association between protein-energy wasting
leading to weight loss and mortality in patients undergoing
maintenance HD therapy is well documented [32, 33].
Moreover, there is an increased risk of hospitalization among
patients under HD who are underweight [34]. Probiotic sup-
plementation might promote weight gain by altering intestinal
flora [35]; however, current evidence is still controversial [36].
In the current study, synbiotic supplementation for 12 weeks
to diabetic patients under HD resulted in a significant reduc-
tion in FPG, insulin, and HOMA-IR and an increase in
QUICKI score, but did not affect lipid profiles. These im-
provements in glucose homeostasis might be contributed to
the observed weight gain in our study. Consistent with our
findings, a 28-week synbiotic supplementation with 2 ×
108 CFU/day of seven strains of bacteria (Lactobacillus casei,
Lactobacillus rhamnosus, Streptococcus thermophilus,
Bifidobacterium breve , Lactobacillus acidophilus ,
Bifidobacterium longum, and Lactobacillus bulgaricus) and
prebiotics (250 mg fructooligosaccharide) significantly im-
proved glucose metabolism in patients with MetS [15].
Furthermore, in a meta-analysis conducted by Hadi et al. [9],
synbiotic supplementation to NAFLD patients decreased
fasting glucose and insulin levels, yet did not change
HOMA-IR. In contrast to what we found, Rajkumar et al.
[16] reported that probiotic intake containing 2 × 109 CFU/
day Lactobacillus salivarius alone or in combination with
fructooligosaccharide (10 g/day) to healthy volunteers for
6 weeks decreased triglycerides and total- and LDL-
cholesterol and increased HDL-cholesterol levels.
Furthermore, consumption of a synbiotic containing
Lactobacillus acidophilus and Bifidobacterium bifidum
(108 CFU/day) plus oligofructose by elderly patients with
T2DM increased HDL-cholesterol concentrations [37]. The
absence of beneficial effects of synbiotics on lipid profiles in
our study might be due to the difference in study participants,
baseline levels of measured markers, dosage, and type of pro-
biotic and prebiotic used.
Insulin resistance and hyperglycemia might increase
the risk of protein-energy malnutrition, as well as car-
diovascular morbidity and mortality in patients with
ESRD [38, 39]. Therefore, improved glucose homeosta-
sis might prevent malnutrition, inflammation, and ath-
erosclerosis syndrome, the latter being one of the most
important phenomenon in patients undergoing HD treat-
ment. Promising effects of synbiotics on glycemic con-
trol might be due to increased production of SCFA,
especially butyrate that increases fatty acid beta-
oxidation and GLP-1 secretion [17], and modulates the
expression of lipogenic and glucogenic gene such as
peroxisome proliferator-activated receptor gamma, glu-
cose transporter type 4, and glucose-6-pohspahtase
[18]. Probiotics also might decrease toll-like receptor
activity, which in turn reduces muscle insulin resistance
caused by inflammatory signaling pathway [40].
Table 1 General characteristics
of study participants Placebo group (n = 30) Synbiotic group (n = 30) P
1
Gender (%)
Male 21 (70.0) 21 (70.0) 1.00†
Female 9 (30.0) 9 (30.0)
Type of diabetes (%)
Type 1 2 (6.7) 2 (6.7) 1.00†
Type 2 28 (93.3) 28 (93.3)
Age (years) 62.8 ± 14.8 62.8 ± 12.7 0.98
Height (cm) 161.4 ± 10.5 164.8 ± 11.0 0.22
Weight at study baseline (kg) 70.3 ± 14.3 71.9 ± 15.8 0.68
Weight at end-of-trial (kg) 69.8 ± 13.9 72.6 ± 15.4 0.47
Weight change (kg) − 0.5 ± 1.9 0.7 ± 2.0 0.02
BMI at study baseline (kg/m2) 26.9 ± 4.7 26.4 ± 5.4 0.70
BMI at end-of-trial (kg/m2) 26.7 ± 4.6 26.7 ± 5.4 0.96
BMI change (kg/m2) − 0.2 ± 0.7 0.3 ± 0.8 0.02
Years on dialysis 3.9 ± 1.2 3.6 ± 1.1 0.50
Data are means ± SDs
1Obtained from independent t test
†Obtained from Pearson’s chi-square test
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Effects on Biomarkers of Inflammation and Oxidative
Stress
Current findings showed that the consumption of synbiotic by
diabetic patients under HD significantly reduced hs-CRP and
MDA and significantly increased TAC and GSH, but did not
significantly change NO levels. There are discrepant results
reporting different effects of synbiotic supplementation on
biomarkers of inflammation and oxidative stress. Consistent
with our findings, Kleniewska et al. [41] observed that taking
synbiotic supplements containing 4 × 108 CFU/day
Lactobacillus casei and 400 mg inulin for 7 weeks by healthy
volunteers significantly improved MDA and GSH concentra-
tions. Moreover, in a meta-analysis conducted by Hadi et al.
[9], synbiotic supplementation to NAFLD patients led to a
significant reduction in hs-CRP levels. Others have reported
that prebiotic and probiotic supplementation decreased oxida-
tive stress [42, 43], while some of them failed to detect a
significant effect of probiotics on antioxidant status [44, 45].
Our previous study indicated that synbiotic supplementation
containing three probiotic bacteria species Lactobacillus
acidophilus, Lactobacillus casei, and Bifidobacterium
bifidum (2 × 109 CFU/g each) plus 800 mg inulin significantly
reduced hs-CRP andMDA and increased NO levels in diabet-
ic patients, but did not affect other antioxidant markers [20]. In
contrast to our findings, synbiotic supplementation did not
decrease hs-CRP levels in women with polycystic ovary syn-
drome [46] or overweight children [21]. High serum levels of
CRP in patients under HD are associated with all-cause and
CVD mortality [47]. Inflammation and elevated oxidative
stress presented in ESRD patients aggravate disease condition
and are associated with a large number of ESRD complica-
tions, including protein-energy wasting and atherosclerosis
[48]. Current evidence has demonstrated that probiotic and
synbiotic intake may decrease the production of pro-
inflammatory cytokines, inhibit lipid peroxidation such as
MDA, and increase the activity of antioxidant enzymes [18].
In the current study, we observed a significant reduction in
inflammation after synbiotic ingestion which was accompa-
nied by the activation of G protein-coupled receptor 41 and
Table 2 Metabolic profiles, biomarkers of inflammation, and oxidative stress at study baseline and after the 12-week intervention in patients with
diabetic hemodialysis that received either synbiotic supplements or placebo
Variables Placebo group (n = 30) Synbiotic group (n = 30) Difference in outcome measures between
synbiotic and placebo treatment groups1
Baseline Week 12 Baseline Week 12 β (95% CI) P2
FPG (mg/dL) 121.5 ± 43.9 128.2 ± 47.4 123.2 ± 57.6 115.9 ± 43.0 − 13.56 (− 23.82, − 3.30) 0.01
Insulin (μIU/mL) 17.7 ± 9.1 18.9 ± 8.3 18.7 ± 6.1 14.2 ± 6.5 − 5.49 (− 6.92, − 4.05) < 0.001
HOMA-IR 5.5 ± 3.9 6.1 ± 4.1 6.1 ± 4.4 4.4 ± 3.3 − 2.25 (− 3.02, − 1.48) < 0.001
QUICKI 0.30 ± 0.02 0.30 ± 0.03 0.30 ± 0.02 0.32 ± 0.02 0.02 (0.01, 0.02) < 0.001
HbA1c (%) 6.2 ± 0.9 6.1 ± 1.1 6.4 ± 1.3 5.9 ± 1.1 − 0.44 (− 0.79, − 0.09) 0.01
Triglycerides (mg/dL) 137.5 ± 56.6 141.6 ± 64.3 131.5 ± 52.8 123.3 ± 44.7 − 12.52 (− 27.62, 2.57) 0.10
VLDL-cholesterol (mg/dL) 27.5 ± 11.3 28.3 ± 12.9 26.3 ± 10.5 24.7 ± 8.9 − 2.50 (− 5.52, 0.51) 0.10
Total cholesterol (mg/dL) 140.2 ± 41.7 143.0 ± 42.4 142.6 ± 46.1 138.8 ± 30.7 − 5.41 (− 16.98, 6.16) 0.35
LDL-cholesterol (mg/dL) 75.4 ± 37.7 79.3 ± 38.6 84.2 ± 42.8 85.0 ± 30.6 0.18 (− 11.40, 11.77) 0.97
HDL-cholesterol (mg/dL) 37.3 ± 8.5 35.4 ± 9.7 32.0 ± 8.9 29.1 ± 7.7 − 1.96 (− 4.88, 0.94) 0.18
Total-/HDL-cholesterol ratio 3.9 ± 1.3 4.4 ± 2.5 4.6 ± 1.5 5.0 ± 1.5 − 0.10 (− 0.86, 0.66) 0.79
hs-CRP (ng/mL) 5091.0 ± 2700.0 5627.5 ± 2906.6 6008.3 ± 3133.7 3396.7 ± 2562.9 − 2930.48 (− 3741.15, − 2119.80) < 0.001
NO (μmol/L) 62.2 ± 16.7 62.6 ± 22.6 63.5 ± 13.5 65.9 ± 13.4 2.88 (− 4.89, 10.66) 0.46
TAC (mmol/L) 1233.3 ± 295.8 1183.7 ± 231.9 1223.2 ± 224.5 1318.8 ± 236.7 142.99 (61.72, 224.25) 0.001
GSH (μmol/L) 564.4 ± 221.2 513.8 ± 172.4 654.9 ± 32.6 702.9 ± 56.4 131.11 (89.35, 172.87) < 0.001
MDA (μmol/L) 3.1 ± 1.0 3.2 ± 1.1 2.4 ± 0.7 2.1 ± 0.6 − 0.60 (− 0.99, − 0.20) 0.003
SGA score 10.5 ± 2.3 10.6 ± 2.3 9.7 ± 2.7 8.6 ± 2.3 − 1.5 (− 2.31, − 0.76) < 0.001
Data are mean ± SDs
1 BOutcome measures^ refer to the change in values of measures of interest between baseline and week 12. β (difference in the mean outcome measures
between treatment groups (synbiotic group = 1 and placebo group = 0))
2 Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age, and baseline BMI)
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-insulin resistance; HDL-cholesterol, high-density
lipoprotein-cholesterol;Hs-CRP, high-sensitivity C-reactive protein; LDL-cholesterol, low-density lipoprotein-cholesterol;MDA, malondialdehyde;NO,
nitric oxide; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low-density lipoprotein-cholesterol; SGA, subjective global
assessment; TAC, total antioxidant capacity
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GPR43 [49], and reduction of the activity of nuclear factor-κB
[50]. The up-regulation of gene expression of interleukin-18
by SCFA [51] and increased production of methylketones
family in the colon, following the intake of synbiotic, [52]
might explain its anti-inflammatory effects. Unfortunately,
we did not measure SCFA levels in the current study as a
mechanism for the observed effects, but this measurement is
recommended in future studies.
This study had several limitations. We were not able to
measure fecal bacteria loads before and after probiotic supple-
mentation. Due to lack of appropriate funding, we could not
quantify circulating interleukin-6 and tumor necrosis factor-α
levels and gene expression related to insulin and inflammation
signaling pathway in diabetic patients under HD. In addition,
we did not measure SCFA and GLP-1 levels as a mechanism
for the observed effects. In the current study, all participants
were from a limited area and similar genetics. Renal and met-
abolic health, among all health parameters, was associated
with many factors including genetics. This should be consid-
ered in our findings interpretation.
Conclusions
Overall, we found that taking synbiotic for 12 weeks by dia-
betic patients undergoing HD significantly improved health
parameters, including glycemic control and biomarkers of in-
flammation and oxidative stress, but did not significantly af-
fect lipid profiles. Our findings suggest that synbiotic supple-
mentation may be relevance valuable therapeutic agent for
diabetic patients undergoing HD. Further research is recom-
mended to confirm the beneficial effects of synbiotic supple-
mentation in other populations.
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